In Spite of Big Pharma's Productivity Crisis in Developing New Products, Drug Repositioning is Currently Being Utilized in a Limited Capacity According to New Report

Business Wire, June 11, 2007

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c59322) has announced the addition of Drug Repositioning Strategies: Innovative Strategies to Boost Pipeline Productivity to their offering.

Report overview

Key findings

Drug repositioning is regarded as the pharma industry's solution to falling R&D productivity and weakening product pipelines, successful repositioned drugs such as raloxifene (Evista; Lilly), thalidomide (Thalomid; Celegene), (Exubera;Pfizer/Nektar) have enabledinnovative companies to adopt lower risk strategies to optimize product pipelines. Drug Repositioning Strategies is a new report that provides in-depth analysis of leading pharma companies that are using novel technologies to reposition failed, marketed or reformulated compounds. This report analyzes strategies that are currently being employed by the leading players and the associated opportunities and challenges arising from them, enabling you to understand trends in the market and optimize your R&D pipeline. Use this report to examine current approaches to drug repositioning and identify successful technologies and business models that can help your organization deliver enhanced clinical and commercial output.

Drug Repositioning Strategies

Innovative strategies to boost pipeline productivity

- The number of deals between pharma and external drug repositioning partners has risen over the past 3 years. Companies with an active interest in this area include Bayer, Roche, Merck, Organon, Eli Lilly, Pfizer and Novartis.

- Repositioning marketed products for new indications will remain the most attractive repositioning strategy. The common approaches include drug combinations, broad indications discovery and the application of novel delivery technologies.

- Technologies that enable targeted delivery, alternative delivery routes, controlled delivery and prodrugs represent a large and growing market. Companies active in these areas will continue to be involved in repositioning projects for the foreseeable future

- As more clinical data for stalled drug candidates becomes available in the next five years, many failed compounds will migrate along the product development pipeline. This will drive the repositioning efforts of a number of pharma companies.

Key questions answered

- What impact will drug repositioning have on the pharma industry's product pipelines?

- Which companies are providing high-quality indication discovery services for failed compounds?

- How is drug repositioning being used to optimize drug pipelines?

- Which companies are utilizing libraries of marketed and off patent compounds for indications discovery?

- When will the first drugs developed by drug repositioning enter the marketplace?

Key issues examined in this report

- In spite of big pharma's productivity crisis in developing new products, drug repositioning is currently being utilized in a limited capacity. How and when will this strategy drive up the ROI on compounds that failed as late as Phase 2 or 3?

- The realization that drugs often have activity in more than one indication is growing. New technologies, presented in this report, are being utilized successfully for indications discovery- the first step of the drug repositioning process for both failed and marketed compounds.

- A large number of marketed drugs are due to come off patent in the next few years, providing a good supply of compounds for specialty pharma companies to test for activity on proprietary technology platforms

- Reformulation offers the potential for safer, more efficacious products that are easier for patients to use. This improves compliance with treatment regimes and increases patient satisfaction, while lowering the overall cost of treatment.

Chapter Outline:

Executive Summary

Chapter 1 Introduction

Chapter 2 Repositioning failed compounds

Chapter 3 Repositioning marketed compounds

Chapter 4 Drug repositioning through reformulation

Chapter 5 Intellectual Property and regulatory issues

Chapter 6 Challenges of drug repositioning

Chapter 7 The future of repositioning

List of Figures

List of Tables

Companies Mentioned:

- Altea Therapeutics

- Bionaut

- DanioLab

- Egalet

- Elan

- Heidelberg Pharma

- KineMed

- Melior Pharmaceuticals

- Penwest

- SkyePharma

- XenoPort

For more information visit http://www.researchandmarkets.com/reports/c59322

Source: Business Insights